Doximity

Digital Transformation And Telehealth Will Revolutionize Healthcare Collaboration

AnalystHighTarget

Not Invested

Community Contributor

Published

23 Apr 25

Updated

12 Dec 25

n/a

AnalystHighTarget's Fair Value

n/a

-15.9%

-4.5%

-15.9%

-4.5%

You can edit this narrative until Dec 13 5:05 AM. Then, changes will post as Updates.

Author's Valuation

US$8347.2% undervalued

AnalystHighTarget Fair Value

Narrative

Updates3

Shared on 12 Dec 25

Fair value Increased 5.63%

DOCS: Budget Flush And Ad Shift Will Drive Shares Higher

Analysts have lifted their Doximity fair value estimate to $83.00 from $78.58, reflecting stronger expected revenue growth and improving long term growth visibility, which they believe more than offset lower margin assumptions and a higher required return. Analyst Commentary Bullish analysts highlight that the recent pullback in Doximity shares has created a compelling entry point, with the stock now trading at what they view as an unjustified discount to the broader vertical software peer group.

Shared on 07 May 25

Fair value Decreased 12%

Shared on 30 Apr 25

Fair value Increased 14%

AnalystHighTarget made no meaningful changes to valuation assumptions.

AnalystHighTarget Fair Value

US$83

47.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

9.50%

Healthtech revenue growth rate

13.17%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.20%

Calculation

US$321.48m

Earnings '28

62.14x

PE Ratio '28

US$19.98b

Market Cap '28

US$19.98b

Market Cap '28

190.19m

No. shares '28

US$105.04

Share Price '28

US$105.04 Share Price '28

Discounted to 2025 @ 8.20% p.a.

US$82.92

Fair Value '25